| Literature DB >> 34472371 |
Willeke R Naaktgeboren1,2, David Binyam2, Martijn M Stuiver1,3,4, Neil K Aaronson1, Arco J Teske5, Wim H van Harten1,6, Wim G Groen1, Anne M May2.
Abstract
Background Physical exercise is an intervention that might protect against doxorubicin-induced cardiotoxicity. In this meta-analysis and systematic review, we aimed to estimate the effect of exercise on doxorubicin-induced cardiotoxicity and to evaluate mechanisms underlying exercise-mediated cardioprotection using (pre)clinical evidence. Methods and Results We conducted a systematic search in PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) databases. Cochrane's and Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) risk-of-bias tools were used to assess the validity of human and animal studies, respectively. Cardiotoxicity outcomes reported by ≥3 studies were pooled and structured around the type of exercise intervention. Forty articles were included, of which 3 were clinical studies. Overall, in humans (sample sizes ranging from 24 to 61), results were indicative of exercise-mediated cardioprotection, yet they were not sufficient to establish whether physical exercise protects against doxorubicin-induced cardiotoxicity. In animal studies (n=37), a pooled analysis demonstrated that forced exercise interventions significantly mitigated in vivo and ex vivo doxorubicin-induced cardiotoxicity compared with nonexercised controls. Similar yet slightly smaller effects were found for voluntary exercise interventions. We identified oxidative stress and related pathways, and less doxorubicin accumulation as mechanisms underlying exercise-induced cardioprotection, of which the latter could act as an overarching mechanism. Conclusions Animal studies indicate that various exercise interventions can protect against doxorubicin-induced cardiotoxicity in rodents. Less doxorubicin accumulation in cardiac tissue could be a key underlying mechanism. Given the preclinical evidence and limited availability of clinical data, larger and methodologically rigorous clinical studies are needed to clarify the role of physical exercise in preventing cardiotoxicity in patients with cancer. Registration URL: https://www.crd.york.ac.uk/prospero; Unique identifier: CRD42019118218.Entities:
Keywords: anthracyclines; cardiotoxicity; exercise; meta‐analysis
Mesh:
Substances:
Year: 2021 PMID: 34472371 PMCID: PMC8649276 DOI: 10.1161/JAHA.121.021580
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1Flow diagram depicting the search process.
The format provided by Moger et al in the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses statement was used.
Characteristics of the Study Protocols
| Reference | Study population | Study characteristics | Doxorubicin characteristics | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients/animals | Sex | Age | Experimental groups (n) | Exercise specifications | Exercise timing with respect to doxorubicin infusion | Control groups (n) | Timing of cardiotoxicity assessment | Timing of doxorubicin | Dose, mg/kg | No. of doses (time) | |
| Clinical studies | |||||||||||
| Kirkham, 2017 | Patients with stage I–III breast cancer, scheduled for doxorubicin‐containing therapy | Female | 50 y | Treadmill (13) | Acute: single bout of 30 min at 70% HRmax | Preconditioning | No vigorous exercise for 72 h before and 48 h after treatment (11) | Before first treatment (baseline) and 24–48 h After doxorubicin treatment | 24 h After treadmill | 60 mg/m2 | 1 |
| Kirkham, 2018 | Patients with stage I–III breast cancer, scheduled for doxorubicin‐containing therapy | Female | 50 y | Treadmill (13) | Chronic: 4 bouts of 30 min across 6–9 wk before each doxorubicin administration, 70% HRmax | Concomitant | No vigorous exercise for 72 h before and 48 h after treatment (11) | Before first treatment (baseline) and 7–14 d after last treatment | 24 h After each treadmill | Mean total 236 mg/m2 | 4 (6–9 wk) |
| Ma, 2018 | Patients with breast cancer, after operation | Female | 43.1 y | Treadmill (31) | Chronic: 3 d/wk for 16 wk, 70% HRmax | Concomitant | No guidance in sports, performed normal daily activities (33) | After last exercise bout, time NS | NS | NS | 4 (16 wk) |
| Animal studies | |||||||||||
| Ahmadian, 2018 | Wistar rats | Male | 3 mo, 16 mo, and 32 mo | Treadmill (8 per group) | Chronic : 5 d/wk for 3 wk, 15–17 m/min, 25–39 min/d | Preconditioning |
Sedentary+doxorubicin (8 per group) Treadmill+saline (8 per group) | 24 h After doxorubicin | 24 h After treadmill | 20 | 1 |
| Alihemmati, 2019 | Wister rats | Male | NS | Treadmill (6) | Chronic: 5 d/wk for 6 wk, intensity 40%–90% VO2max, 60 min/d | Preconditioning |
Sedentary+saline (6) Sedentary+doxorubicin (6) Treadmill+saline (6) | 72 h After doxorubicin | After exercise | 20 | 1 |
| Ascensão, 2006 | Wistar rats | Male | 6–8 wk | Treadmill (6) | Chronic: 5 d/wk for 14 wk. Building up to 90 min/d, 30 m/min (grade 6%) by wk 5 | Preconditioning |
Sedentary+saline (6) Sedentary+doxorubicin (6) Treadmill+saline (6) | 24 h After doxorubicin | 24 h After treadmill | 20 | 1 |
| Ascensão, 2011 | Wistar rats | Male | 6 wk | Treadmill (5) | Acute: single bout of 60 min, ≈5 min at 15 m/min 0% gradient, ≈10 min 23 m/min 0% gradient, ≈45 min 25 m/min 5% gradient | Preconditioning |
Sedentary+saline (5) Sedentary+doxorubicin (5) Treadmill+saline (5) | 5 d After doxorubicin | 24 h After treadmill | 20 | 1 |
| Ascensão, 2005 | Wistar rats | Male | 6–8 wk | Treadmill (10) | Chronic: 5 d/wk for 14 wk. Building up to 30 m/min (6% grade), 90 min/d | Preconditioning |
Sedentary+saline (10) Sedentary+doxorubicin (10) Treadmill+saline (10) | 24 h After doxorubicin | 24 h After treadmill | 20 | 1 |
| Ascensão, 2005 | Charles River CD1 mice | Male | 6–8 wk | ST (11) | Chronic 5 d/wk for 14 wk. 1 h/d | Preconditioning |
Sedentary+saline (11) Sedentary+doxorubicin (11) ST+saline (11) | 24 h After doxorubicin | 24 h After ST | 20 | 1 |
| Ashrafi, 2012 | Wistar rats | Male | 8 wk |
Treadmill+doxorubicin 10 mg/kg (8) Treadmill+doxorubicin 20 mg/kg (8) | Chronic: 5 d/wk for 3 wk. 15–17 m/min, 25–39 min/d | Preconditioning |
Sedentary+saline (8) Sedentary+doxorubicin 10 mg/kg (8) Sedentary+doxorubicin 20 mg/kg (8) Treadmill+saline (8) | 24 h After doxorubicin | 24 h After treadmill |
1. 10 2. 20 | 1 |
| Chicco, 2005 | Spraque–Dawley rats | Female | NS | WR (7) | Chronic:voluntary for 8 wk | Preconditioning |
Sedentary+saline (6) Sedentary+doxorubicin (7) WR+saline (8) | During and after perfusion | Directly after WR, ex vivo perfusion | 10 µM | For 1 h |
| Chicco, 2006 | Spraque‐Dawley rats | Male | NS | Treadmill (8) | Chronic: 5 d/wk for 2 wk. 15 m/min, 20 min/d | Concomitant |
Sedentary+saline (6) Sedentary+doxorubicin (8) Treadmill+saline (6) | 5 d After exercise | During treadmill | 2.5 | 6 (2 wk) |
| Chicco, 2006 | Spraque‐Dawley rats | Male | NS | Treadmill (15) | Chronic: 5 d/wk for 12 wk. Building up to 15–27 m/min (0–5% gradient), 20–60 min/d | Preconditioning |
Sedentary+saline (6) Sedentary+doxorubicin (15) Treadmill+saline (6) | 5 d After doxorubicin | 24 h After treadmill | 15 | 1 |
| Dolinsky, 2013 | C57BL6 mice | Female | 10 wk | Treadmill (9–11) | Chronic: 5 d/wk for 8 wk, building up to 18 m/min, 45 min/d | Concomitant |
Sedentary+saline (9–11) Sedentary+doxorubicin (9–11) Sedentary+doxorubicin+resveratrol (9–11) | 48 h After exercise | During treadmill | 8 | 4 (4 wk) |
| Farzanegi, 2019 | Wistar rats | NS | 40–50 wk | ST (6) | Chronic: 3 d/wk for 8 wk. Building up from 5 to 30 min/d | Concomitant |
Sedentary+saline (6) Sedentary+doxorubicin (6) Sedentary+doxorubicin+saline (6) Sedentary+doxorubicin+GA (6) ST+doxorubicin+GA (6) | Directly after completion of exercise | During ST in week 1 | 8.5 | 1 |
| Hall, 2019 | Sprague‐Dawley rats | Female | 10 wk | WR (8) | Chronic: voluntary for 17 wk | Preconditioning |
Sedentary+saline (6) Sedentary+CR (6) Saline+WR (6) Saline+CR+WR (8) Doxorubicin (8) CR+doxorubicin (8) CR+doxorubicin+WR (8) | 5 d After doxorubicin | 5 d After WR | 15 | 1 |
| Hydock, 2008 | Spraque‐Dawley rats | Male | NS |
Treadmill (24) WR (21) | Chronic: 1. 5 d/wk for 10 wk. 20–60 min/d, 20–30 m/min (0–18% grade). 2. voluntary for 10 wk | Preconditioning |
Sedentary+saline (30) Sedentary+doxorubicin (28) Treadmill+saline (24) WR+saline (20) | 5 Or 10 d after doxorubicin | 24 h After treadmill/WR | 10 | 1 |
| Hydock, 2009 | Spraque‐Dawley rats | Female | NS | WR (9) | Chronic: voluntary for 7 wk | Concomitant |
Sedentary (10) Sedentary+doxorubicin (8) | 7 d After doxorubicin | During WR, after wk 1 | 2.5 | 6 (6 wk) |
| Hydock, 2011 | Spraque‐Dawley rats | Male | NS |
Treadmill (17) WR (23) | Chronic: 5 d/wk for 10 wk. 30 m/min, 60 min/d. Voluntary for 10 wk | Preconditioning |
Sedentary+saline (11) Sedentary+doxorubicin (14) Treadmill+saline (12) WR+saline (17) | 4 wk After doxorubicin | 24 h After treadmill/WR | 1 | 10 (10 d) |
| Hydock, 2012 | Spraque‐Dawley rats | Female | NS |
WR+doxorubicindly (9) WR+doxorubicinwk (10) | Chronic: voluntary for 10 wk | Concomitant |
Sedentary+salinedly (8) Sedentary+salinewk (7) Sedentary+doxorubicindly (15) Sedentary+doxorubicinwk (10) WR+salinedly (8) WR+salinewk (8) | Directly after completion of exercise | During WR |
1dly 2.5wk |
15 (15 d) 6 (6 wk) |
| Jensen, 2013 | Spraque‐Dawley rats | Female | 10–11 wk |
Treadmill (47–58) WR (40–51) | Chronic: 5 d/wk for 10 wk. 13–30 m/min (5%–18% grade), 60 min/d. Voluntary for 10 wk | Preconditioning |
Sedentary+saline (5–9) Sedentary+doxorubicin (38–61) | 1, 3, 5, 7 Or 9 d after doxorubicin | 24 h After treadmill/WR | 10 | 1 |
| Ji, 1994 | Spraque‐Dawley rats | Female | 6 mo |
Treadmill (7) Treadmill+REC (7) |
Acute: single bout Until exhaustion Treadmill+REC=30 min recovery | Postconditioning |
Sedentary+saline (13) Sedentary+doxorubicin (7) Treadmill+saline (6) Treadmill+REC+saline (7) | Directly after exercise | 24 h And 30 min before treadmill/treadmill+REC | 4 | 2 |
| Kanter, 1985 | Swiss White mice | Male | 5 wk | ST (20) | Chronic: 5 d/wk for 21 wk. Building up to 1 h/d | Concomitant |
Sedentary (20) Sedentary+doxorubicin (22) ST (21) | After 9 wk of exercise and after 21 wk. Histology only assessed after 21 wk | During treadmill, starting from wk 9 | 4 | 10 (7 wk) |
| Kavazis, 2010 | Spraque‐Dawley rats | Male | 4–6 mo |
Treadmill (7) Treadmillcold (6) | Chronic: 5 d/wk for 5 d. 30 m/min, 60 min/d. Both in cold (4°C) and normal temperature | Preconditioning |
Sedentary+saline (8+7) Sedentary+doxorubicin (6) Treadmill+saline (7) Treadmillcold+saline (6) | 24 h After doxorubicin | Directly after treadmill | 20 | 1 |
| Kavazis, 2014 | Spraque‐Dawley rats | Male | 6 mo | Treadmill (6) | Chronic: 1 time per d for 5 d. 30 m/min, 60 min/d | Preconditioning |
Sedentary+saline (6) Sedentary+doxorubicin (6) Treadmill+saline (6) | 24 h After doxorubicin | 24 h After treadmill | 20 | 1 |
| Lee, 2020 | C57BL6 mice | Male | 8 wk | Treadmill (10) | Chronic: 5 d/wk for 4 wk. 13 m/min, 60 min/d | Postconditioning |
Sedentary+saline (10) Sedentary+doxorubicin (10) | 24 h After exercise | 24 Before exerciseE | 20 | 4 (4 wk) |
| Lien, 2015 | Spraque‐Dawley rats | Male | 10 wk |
Treadmill+doxorubicin 10 mg/kg (10) Treadmill+doxorubicin 15 mg/kg (13) WR+doxorubicin 10 mg/kg (10) WR+doxorubicin 15 mg/kg (12) | Chronic: 1 time per d for 5 d. 24 m/min, 60 min/d. | Preconditioning |
Sedentary+saline (14) Sedentary+doxorubicin 10 mg/kg (10) Sedentary+doxorubicin 15 mg/kg (13) WR+saline (13) Treadmill+saline (13) | 5 d After doxorubicin | 24 h After treadmill/WR |
10 15 | 1 |
| Mackay, 2019 | C57BL6 mice | Male | 5 wk | Treadmill (8) | Chronic: 1 time per d for 5 d. On 70% of max speed, 60 min/d | Concomitant |
Sedentary+saline (9) Sedentary+doxorubicin (8) Treadmill+saline (11) MET+sedentary+saline (13) MET+doxorubicin (7) | 3 d After doxorubicin | 1 h After treadmill | 15 | 1 |
| Marques‐Aleixo, 2015 | Spraque‐Dawley rats | Male | 6 wk |
Treadmill (6) WR (6) | Chronic: 5 d/wk for 12 wk, 18–27 m/min, 60 min/d. Voluntary: 12 wk | Concomitant |
Sedentary+saline (6) Sedentary+doxorubicin (6) Treadmill+saline (6) WR+saline (6) | 48 h After exercise | During treadmill/WR, starting from wk 5 | 2 | 7 (7 wk) |
| Marques‐Aleixo, 2018 | Spraque‐Dawley rats | Male | 6 wk |
Treadmill (NS) WR (NS) | Chronic:. 5 d/wk for 14 wk, 18–27 m/min, 60 min/d. Voluntary: 14 wk | Concomitant |
Sedentary+saline (NS) Sedentary+doxorubicin (NS) Treadmill+saline (NS) WR+saline (NS) | 48 h After exercise | During treadmill/WR, starting from wk 5 | 2 | 7 (7 wk) |
| Morton, 2019 | Spraque‐Dawley rats | Female | 6 mo | Treadmill (10) | Chronic: 5 d/wk for 2 wk. 30 m/min, 60 min/d | Preconditioning |
Sedentary+saline (10) Sedentary+doxorubicin (10) Treadmill+saline (10) | 48 h After doxorubicin | 24 h After treadmill | 20 | 1 |
| Parry, 2015 | Fischer 344 rats (inoculated with tumor cells after wk 11) | Female | 12 wk | WR (36) | Chronic: voluntary for 12–13 wk | Preconditioning |
Sedentary+saline (30) Sedentary+doxorubicin (36) WR+saline (30) | 1, 3, Or 5 d after doxorubicin | 24 h After tumor reached 1 cm | 12 | 1 |
| Pfannenstiel, 2018 | Spraque‐Dawley rats | Male | 10 wk | RT (15) | Chronic: RT for 12 wk by encouraging rats to stand up heightening the food/water supply | Preconditioning |
Sedentary+saline (9) Sedentary+doxorubicin (15) RT+saline (9) | 5 d After doxorubicin | 24 h After RT | 12.5 | 1 |
| Phungphong, 2020 | Sprague‐Dawley rats | Female | 9 wk | Treadmill | Chronic: 5 d/wk for 14 d, 21 m/min, 2x 10–30 min/d | Concomitant |
Sedentary/sham operated (11) OVX (12) OVX+doxorubicin (11) OVX+doxorubicin+estrogen (12) OVX+doxorubicin+mast cell stabilizer (13) | 48 h After exercise | During treadmill | 2.5 | 6 (2 d) |
| Shirinbayan, 2012 | Wistar rats | Male | 10 wk | Treadmill (8) | Chronic: 5 d/wk for 3 wk, 15–17 m/min, 23–39 min/d | Preconditioning |
Sedentary+saline (8) Sedentary+doxorubicin 10 mg/kg (8) Sedentary+doxorubicin 20 mg/kg (8) Treadmill+saline (8) | 24 h After doxorubicin | 24 h After treadmill |
10 20 | 1 |
| Smuder, 2013 | Spraque‐Dawley rats | Male | 6 mo | Treadmill (6) | Chronic: 1 time per d for 10 d, building up to 30 m/min, 60 min/d | Preconditioning |
Sedentary+saline (6) Sedentary+doxorubicin (6) Treadmill+saline (6) | 24 h After doxorubicin | Directly after treadmill | 20 | 1 |
| Sturgeon, 2014 | C57BL6 mice (injected with melanoma cells) | Male | 6–8 wk | Treadmill (9) | Chronic: 5 d/w for 2 wk, 10 m/min, 45 min/d | Concomitant |
Sedentary+saline (7) Sedentary+doxorubicin (8) Treadmill+saline (8) | 48 h After exercise | During treadmill | 2 | 2 (2 wk) |
| Werner, 2008 |
C57BL6 mice eNOS−/− micecmar TERT−/− mice | Male | 8 wk | WR (6–12) | Chronic: voluntary for 3 wk | Preconditioning |
Sedentary+doxorubicin (8–12) Sedentary (8–12) WR6 mo Sedentary6 mo | NS | After WR (further NS) | 22.5 | 1 (24 h) |
| Wonders,2008 | Spraque‐Dawley rats | Male | NS | Treadmill (NS) | Acute: single bout of 60 min, ≈5 min at 15 m/min 0% gradient, ≈10 min 23 m/min 0% gradient, ≈45 min 25 m/min 5% gradient | Preconditioning |
Sedentary+saline (NS) Sedentary+doxorubicin (NS) Treadmill+saline (NS) | 5 d After doxorubicin | 24 h after treadmill | 15 | 1 |
| Yang, 2020 | Sprague‐Dawley rats | Male | NS | Treadmill (8) | Chronic: 3 d/wk for 4 wk, 12 m/min, 60 min/d | Concomitant |
Sedentary+saline (8) Sedentary+doxorubicin (8) | 24 h After exercise | 24 After doxorubicin | 20 | 15 (3/wk, 5 wk) |
Experimental groups refers to the intervention these groups underwent. All of the experimental groups also underwent doxorubicin administration. Details regarding doxorubicin are shown in the Doxorubicin characteristics columns. Doxorubicin dosages were specified in other columns in case multiple dosage groups were used. For studies reporting different numbers regarding the study populations, the largest number reported is shown. Doxorubicin administration during exercise was started in the first week of exercise, unless otherwise stated. For Hydock, 2012, "dly" and "wk" in subscript refers to the drug administration schemes, which were respectively daily in 15 consecutive days and weekly in 6 weeks. CR indicates calorie restriction; GA, garlic extract; HRmax, maximum heart rate; MET, metformin; NS, not specified; OVX, ovariectomized; REC, 30 minutes of recovering after exercise; RT, resistance training; ST, swimming training; VO2max, maxium oxygen consumption; and WR, voluntary wheel running.
The study population in the preclinical studies are animals without cancer, unless otherwise stated.
Figure 2Results of the risk of bias assessment for human studies (A), animal studies (B), and quality indicators for animal studies (C).
A, Results of the risk of bias assessment for human studies. The risk of bias was assessed using the Cochrane risk of bias tool. The color of the cells depicts the estimated risk of bias for the studies shown on the y‐axis in the categories shown on the x‐axis. Green, yellow, and red cells represent a low, unclear, and high risk of bias, respectively. Blinding of participants was not possible because of the nature of the intervention. B, Results of the risk of bias assessment for animal studies. The risk of bias was assessed using the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) risk of bias tool. Shown are the percentages of studies that were judged to have an “unclear,” “low,” or “high” risk of bias in the categories depicted on the y‐axis. C, The reporting of quality indicators for animal studies. Shown are the percentages of studies that did or did not report (reported or not reported, respectively) the quality indicators depicted on the y‐axis.
Figure 3Forest plot of forced (A) or voluntary (B) physical exercise (PE) interventions on fractional shortening on echocardiography (in vivo) and of forced (C) or voluntary (D) PE interventions on isolated heart perfusion (ex vivo), compared with nonexercised controls in animal studies.
Results are presented as mean difference (MD) with 95% CI.
Overview of Pathways Studied by the Animal Studies and Their Main Results
| Reference of animal study | Pathway(s) | Effect of PE intervention | Summary of main results |
|---|---|---|---|
| Ahmadian, 2018 |
Marker of oxidative stress (malondialdehyde), antioxidants (SOD), HSP (HSP70), inflammation markers (IL‐10, CRP) | Yes | A preconditioning exercise program had a beneficial effect on antioxidant capacity in all 3 age groups, yet the strongest effect was observed in the group of young rats |
| Alihemmati, 2019 | Apoptosis (Bax, BCL2, caspase 6, and gene and microRNA expression) | Yes | Preconditioning high‐intensity interval training attenuated expression proapoptotic and apoptotic factors and microRNA, counteracting myocardial apoptosis |
|
Ascensão, 2006 | Markers of oxidative stress (gluthatione analysis), Antioxidants (SOD), HSPs (HSP60, HSP70), mitochondrial respiratory functioning | Yes | Heart mitochondria of DOX‐treated animals submitted to an endurance training protocol seemed less susceptible to in vitro anoxia‐reoxygenation compared to DOX‐treated sedentary controls |
| Ascensão, 2011 | Antioxidants (SOD), mPTP, apoptosis (eg, Bax, Bcl2, caspase), mitochondrial functioning | Yes | A single exercise bout mitigated doxorubicin‐induced mPTP susceptibility and mitochondrial dysfunction and altered apoptotic signaling compared with nonexercised controls |
|
Ascensão, 2005 |
Markers of oxidative stress (malondialdehyde, aconitase), antioxidants (SOD), HSPs (HSP60, HSP70), mPTP, apoptosis (Bax, Ncl‐2), mitochondrial functioning | Yes | An endurance treadmill exercise intervention improved antioxidant capacity and attenuated myocardial apoptosis. Histopathology confirmed significant attenuation of cardiotoxic changes in the exercise vs the control group |
| Ascensão, 2005 | Markers of oxidative stress (gluthatione analysis), antioxidants (SOD, catalase), HSPs (HSP60, HSP70), cardiac troponin I | Yes | An endurance swimming exercise program mitigated doxorubicin‐induced oxidative damage compared with controls with positive effects on the glutathione system and HSP60 |
| Ashrafi, 2012 | Markers of oxidative stress (malondialdehyde, NO), antioxidants (SOD, apelin) | Yes | A short‐term PE preconditioning program counteracted doxorubicin‐induced oxidative stress and upregulated oxidative capacity compared with nonexercised controls |
| Chicco, 2005 | Marker of oxidative stress (malondialdehyde), antioxidants (SOD), HSP (HSP72) | Yes | A voluntary wheel‐running preconditioning protocol attenuated doxorubicin‐induced alterations in lipid peroxidation compared with nonexercised controls. In addition, higher levels of HSP72 were observed in the intervention group. Cardiac function tended to be less impaired in the trained group |
| Chicco, 2006 | Marker of oxidative stress (malondialdehyde), antioxidants (SOD), HSP (HSP72), apoptosis (caspase 3), MHC distribution isoforms | Yes | A low‐intensity treadmill exercise protocol mitigated doxorubicin‐induced cardiac dysfunction, HSP72 and apoptotic signaling compared with nonexercised controls. No significant effect on lipid peroxidation, SOD, or MHC distribution was observed |
| Chicco, 2006 | Marker of oxidative stress (malondialdehyde), antioxidants (SOD), HSP (HSP72) | Yes | A preconditioning exercise program significantly mitigated doxorubicin‐induced impairments in cardiac function compared with nonexercised controls. In addition, an increase in lipid peroxidation and greater expression of HSP72 following exercise was observed |
| Dolinsky, 2013 | Marker of oxidative stress (HNE), antioxidants (SOD, glutathione, catalase), SERCA2a expression | Yes | A preconditioning treadmill program counteracted doxorubicin‐induced LV dysfunction, lowered lipid peroxidation, and increased the expression of SER2CA and SOD compared with nonexercised controls |
| Farzanegi, 2019 | Marker of oxidative stress (malondialdehyde), antioxidants (SOD, catalase), HSP (HSP70), inflammation marker (TNF‐α) | Yes | A swimming program concomitant with doxorubicin treatment decreased inflammatory markers (TNF‐a), HSP70, and lipid peroxidation, while improving antioxidant enzymatic activity compared with nonexercised controls |
| Hall, 2019 | Doxorubicin accumulation | Yes | Voluntary wheel running partially prevented doxorubicin‐induced LV dysfunction in vivo and ex vivo and doxorubicin accumulation in cardiac tissue. PE combined with caloric restriction yielded the most cardioprotection |
| Hydock, 2008 | MHC distribution isoforms | Yes | A preconditioning forced and voluntary treadmill program prevented doxorubicin‐induced LV dysfunction in vivo and ex vivo. MHC isoform distribution was preserved following exercise in doxorubicin‐treated animals |
| Hydock, 2009 | MHC distribution isoforms | Yes | Access to voluntary wheel running before doxorubicin treatment significantly increased expression of α‐MHC isoform compared with nonexercised controls |
| Hydock, 2011 | SERCA2a, MHC isoform distribution | Yes | Both forced and voluntary exercise interventions before doxorubicin treatment prevented decline in doxorubicin‐induced LV dysfunction in vivo and ex vivo. The exercise interventions led to a preservation of MHC isoform distribution. No effect of PE on SER2CA was observed |
| Hydock, 2012 | MHC distribution isoforms | Yes | Compared with nonexercised controls, voluntary wheel running prevented in vivo and ex vivo doxorubicin‐induced impairments in LV function and preserved MHC isoform distribution |
| Jensen, 2013 | Doxorubicin accumulation | Yes | Both forced and voluntary PE interventions preserved LV function (in vivo and ex vivo) and reduced doxorubicin accumulation in cardiac tissue compared with nonexercised controls. No difference was observed between the 2 exercise programs |
| Ji, 1993 | Marker of oxidative stress (malondialdehyde), antioxidants (SOD, catalase, glutathione) | No | Low‐dose doxorubicin administration did not substantially impair oxidative functioning in cardiomyocytes, both at rest and during PE |
| Kanter, 1985 | Antioxidants (SOD, catalase, glutathione) | Yes | An endurance swimming protocol concomitant with doxorubicin administration mitigated doxorubicin‐induced histopathological changes compared with nonexercised controls. No significant differences in antioxidants between exercise and nonexercised doxorubicin‐treated animals were found |
| Kavazis, 2010 | Marker of oxidative stress (HNE), antioxidants (SOD, glutathione, catalase), HSP apoptosis (caspase 3, ubiquitine, calpain, TUNEL) | Yes | A short‐term preconditioning PE program increased antioxidant capacity and HSP72 and against mitochondrial damage and apoptosis. Exercise‐induced cardioprotection occurred independently of HSP72 |
| Kavazis, 2014 | Gene expression (FoxO target genes), mitochondrial biogenesis (PGC‐1α receptor) | Yes | Compared with nonexercised controls, the short‐term PE intervention before doxorubicin administration attenuated doxorubicin‐induced alteration in gene expression and protein abundance (PGC‐1α receptor) |
| Lee, 2020 | Antioxidants (eg, SOD, catalase), autophagy/mitophagy (eg, AMPK, mTOR), apoptosis (Bax, BCL2) | Yes | A postconditioning PE program improved basal autophagy and mitophagy and counteracted doxorubicin‐induced oxidative stress compared with nonexercised controls |
| Lien, 2015 | SERCA2a | Yes | Short‐term forced and voluntary exercise interventions prevented doxorubicin‐induced LV dysfunction in vivo and ex vivo compared with nonexercised controls. Both programs preserved SER2CA expression, yet the FTM intervention appeared to be more effective in the higher doxorubicin dose |
| Mackay, 2019 | Markers of oxidative stress (malondialdehyde, glutathione), iron regulation | No | Doxorubicin treatment significantly altered myocardial iron regulation, which was not prevented by a PE program nor metformin treatment before doxorubicin administration |
| Marques‐Aleixo, 2015 | Markers of oxidative stress (malondialdehyde, aconitase), antioxidants (SOD), mitochondrial biogensis (PGC‐1α receptor), mitochondrial functioning | Yes | Both FTM and voluntary wheel running interventions prevented doxorubicin‐induced increase in oxidative stress and preserved mitochondrial functioning. Cardiac ultrastructure alterations (eg, percentage of abnormal mitochondria) were counteracted by the 2 PE programs. No major differences between the 2 PE programs were found |
| Marques‐Aleixo, 2018 | mPTP, autophagy/mitophagy (eg, Beclin2, Pink, Parkin, P62) apoptosis (caspases, Bax, Bcl2) | Yes | Compared with nonexercised controls, forced and voluntary PE programs during doxorubicin treatment mitigated doxorubicin‐induced mPTP susceptibility, and increased autophagic and apoptotic signaling, without substantial differences between the two exercise modalities |
| Morton, 2019 | mPTP, doxorubicin accumulation, reactive oxygen species emission, ABC‐transporter expression | Yes | A short‐term preconditioning PE program prevented doxorubicin‐induced LV dysfunction on echocardiography and mitigated alteration in mPTP susceptibility compared with nonexercised controls. In addition, less mitochondrial doxorubicin accumulation and increased expression of ABC transporters were found |
| Parry, 2015 | Doxorubicin accumulation, multi‐drug resistance protein expression | Yes | In tumor‐inoculated rats, a voluntary wheel running program before doxorubicin treatment preserved cardiac function in vivo as well as ex vivo and reduced doxorubicin accumulation in cardiac tissue compared with nonexercised controls. The exercise program did not interfere with doxorubicin's therapeutic efficacy |
| Pfannenstiel, 2018 | Marker of oxidative stress (malondialdehyde), MHC distribution isoforms | Yes | A resistance training protocol before doxorubicin treatment preserved cardiac function in doxorubicin‐treated animals and protected against MHC isoform distribution changes compared with nonexercised controls. No effect was found in the exercise program with lipid peroxidation |
| Phungphong, 2020 | Markers of oxidative stress (LDH, lipid peroxidation), inflammatory markers (IL‐6), calcium homeostasis, MHC distribution isoforms | Moderately | In ovariectomized rats, preconditioning exercise program attenuated doxorubicin‐induced oxidative stress and cardiac inflammation compared with nonexercised controls. No protective effect on cardiac function following exercise was found |
| Shirinbayan, 2012 | Markers of oxidative stress (malondialdehyde, creatine kinase, creatine phosphokinase‐myocardial band), antioxidants (SOD), HSP (HSP70) | Yes | A preconditioning PE program significantly increased HSP70 and SOD and decreased malondialdehyde as opposed to nonexercised controls, regardless of differences in doxorubicin doses (10 or 20 mg/kg) |
| Smuder, 2013 | Autophagy (mRNA and protein synthesis) | Yes | Compared with nonexercised controls, a preconditioning treadmill program prevented doxorubicin‐induced increase in autophagic signaling |
| Sturgeon, 2014 | MHC distribution isoforms | No | In a murine model with melanoma, a PE program before doxorubicin treatment did not mitigate doxorubicin‐induced LV dysfunction on echocardiography nor changes in MHC isoform distribution but improved doxorubicin's antitumor efficacy compared with nonexercised controls |
| Werner, 2008 | Apoptosis (telomere‐regulating proteins, TUNEL, p53) | Yes | A preconditioning voluntary wheel running program reduced doxorubicin‐induced p53 expression and might prevent cardiomyocyte apoptosis. In animals not treated with doxorubicin, the exercise program upregulated telomere stabilizing proteins compared with nonexercised controls |
| Wonders,2008 | Marker of oxidative stress (malondialdehyde) | Yes | An exercise bout before doxorubicin treatment mitigated doxorubicin‐induced LV dysfunction on isolated heart perfusion and attenuated an increase in oxidative stress compared with nonexercised controls |
| Yang, 2020 | Inflammation markers (AKT, COX‐2), fibrotic markers (TGF‐β) | Yes | A PE program during doxorubicin treatment ameliorated doxorubicin‐induced expression of fibrosis factors and reduced cardiac fibrosis on histopathology compared with nonexercised controls. On echocardiography, LV function was preserved in the exercise group |
AMPK indicates 5'‐adenosine monophosphate‐activated protein kinase; COX‐2, cyclooxygenase‐2; CRP, C‐reactive protein; eNOS, endothelial nitric oxide synthase; FTM, forced treadmill; HNE, 4‐hydroxy‐2‐nonenal protein; HSP, heat shock protein; IL‐6, interleukin 6; IL‐8, interleukin 8; IL‐10, interleukin 10; LDH, lactate dehydrogenase; LV, left ventricular; MHC, myosin heavy chain; mPTP, mitochondrial permeability transition pore; NO, nitric oxide; PE, physical exercise; PGC‐1α, peroxisome proliferator‐activated receptor‐γ coactivator 1α; SERCA2a, sarcoendoplasmatic reticulum calcium ATPase 2a; SOD, superoxide dismutase; TERT, telomerase reverse transcriptase; TGF‐β, transforming growth factor β; TNF‐α, tumor necrosis factor α; and TUNEL, terminal deoxynucleotidal transferase–mediated biotin–deoxyuridine triphosphate nick‐end labeling.
Overview of Available Evidence Per Pathway
| Pathway | No. |
|---|---|
| Antioxidants | 18 |
| HSPs | 10 |
| Cardiac inflammation | 2 |
| Calcium homeostasis | 3 |
| mPTP | 4 |
| PGC‐1α | 2 |
| MHC isoform distribution | 6 |
| Autophagy | 3 |
| Apoptosis | 10 |
| Doxorubicin accumulation | 4 |
HSP indicates heat shock protein; MHC, myosin heavy chain; mPTP, mitochondrial permeability transition pore; and PGC‐1α, peroxisome proliferator‐activated receptor‐γ coactivator 1α.
Figure 4Suggested pathways underlying exercise‐mediated protection against doxorubicin‐induced cardiotoxicity (DIC) in rodents.
Exercise prevents accumulation of doxorubicin in cardiac tissue, thereby inhibiting downstream pathways, through which doxorubicin can induce cardiotoxicity. HSP indicates heat sock protein; MHC, myosin heavy chain; and PGC‐1α, peroxisome proliferator‐activated receptor‐γ coactivator 1α.